Uncertain benefit: the public policy of approving smallpox vaccine research
- PMID: 15249295
- PMCID: PMC1448369
- DOI: 10.2105/ajph.94.6.943
Uncertain benefit: the public policy of approving smallpox vaccine research
Abstract
Without an accurate assessment of the prospect of bioterrorist attack, it is especially challenging to evaluate the protocols for testing smallpox vaccines in the pediatric population. Usual regulatory mechanisms cannot shepherd research protocols with benefits that can only be characterized as "uncertain" in the face of more than minimal risk. When a protocol is placed in a government forum for analysis, the public has a unique opportunity to debate the balancing of research risks and benefits on behalf of children who are unable to assent to research themselves, as well as to express views about vaccination policy broadly. This model for review of pediatric research that may be without benefit will be especially important as challenging studies of various vaccines against a range of infectious properties, such as anthrax and severe acute respiratory syndrome (SARS), emerge.
Similar articles
-
Under scrutiny: smallpox vaccine recommendations.Expert Opin Pharmacother. 2003 Aug;4(8):1207-14. doi: 10.1517/14656566.4.8.1207. Expert Opin Pharmacother. 2003. PMID: 12877631 Review.
-
Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC).MMWR Recomm Rep. 2003 Apr 4;52(RR-7):1-16. MMWR Recomm Rep. 2003. PMID: 12710832
-
Evaluation of 21st-century risks of smallpox vaccination and policy options.Ann Intern Med. 2003 Mar 18;138(6):488-93. doi: 10.7326/0003-4819-138-6-200303180-00014. Ann Intern Med. 2003. PMID: 12639083 Review.
-
Expected adverse events in a mass smallpox vaccination campaign.Eff Clin Pract. 2002 Mar-Apr;5(2):84-90. Eff Clin Pract. 2002. PMID: 11990216
-
Emergency physicians' perspectives on smallpox vaccination.Acad Emerg Med. 2003 Jun;10(6):599-605. doi: 10.1111/j.1553-2712.2003.tb00042.x. Acad Emerg Med. 2003. PMID: 12782519
Cited by
-
Neurologic adverse events associated with smallpox vaccination in the United States--response and comment on reporting of headaches as adverse events after smallpox vaccination among military and civilian personnel.BMC Med. 2006 Nov 10;4:27. doi: 10.1186/1741-7015-4-27. BMC Med. 2006. PMID: 17096855 Free PMC article.
-
The social, political, ethical, and economic aspects of biodefense vaccines.Vaccine. 2009 Nov 5;27 Suppl 4(Suppl 4):D23-7. doi: 10.1016/j.vaccine.2009.08.054. Vaccine. 2009. PMID: 19837281 Free PMC article. Review.
References
-
- Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention. Draft supplemental recommendation of the ACIP: use of smallpox (vaccinia) vaccine. June 2002. Available at: http://www.cdc.gov/nip/smallpox/supp_recs.htm. Accessed January 2003.
-
- Neff JM. The case for abolishing routine childhood smallpox vaccination in the United States. Am J Epidemiol. 1971;93:245–247. - PubMed
-
- Gellman B. 4 nations thought to possess smallpox. Washington Post. 5November2002;A1.
-
- Office for Human Rights Protections. US Department of Health and Human Services Web site. A multicenter, randomized dose response study of the safety, clinical and immune responses of Dryvax administered to children 2 to 5 years of age. Available at: http://ohrp.osophs.dhhs.gov/dpanel/tdryvax.pdf. Accessed November 11, 2002.
-
- Henderson DA, Inglesby TV, Bartlett JG, et al. Smallpox as a biological weapon: medical and public health management. JAMA. 1999;281:2127–2137. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous